Hemostatic markers in acute ischemic stroke: Association with stroke type, severity, and outcome

Stroke

Volumn 27, Issue 8, 1996, Pages 1296-1300

  Feinberg, William M ^a   Erickson, Laurie P ^a   Bruck, Denise ^a   Kittelson, John ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

cerebral infarction; fibrin fibrinogen degradation products; platelet activation; prognosis; thrombosis

Indexed keywords

BIOCHEMICAL MARKER; FIBRINOPEPTIDE A;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STROKE; THROMBOCYTE ACTIVATION; THROMBOSIS;

EID: 0029794987     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.27.8.1296     Document Type: Article

References (47)

1. Mohr JP, Caplan LR, Melski JW, Goldstein RJ, Duncan GW, Kistler JP, Pessin MS, Bleich HL. The Harvard Cooperative Stroke Registry: a prospective registry. Neurology. 1978;28:754-762.
2. Sloan MA. Thrombolysis and stroke: past and future. Arch Neurol. 1986;44:748-768.
3. del Zoppo GH, Zeumer H, Harker LA. Thrombolytic therapy in stroke: possibilities and hazards. Stroke. 1986;17:595-607.
4. Landi G, D'Angelo A, Boccardi E, Candelise L, Mannucci PM, Nobile Orazio E, Morabito A. Hyper-coagulability in acute stroke: prognostic significance. Neurology. 1987;37:1667-1671.
5. D'Angelo AA, Landi G, D'Angelo SV, Nobile Orazio E, Boccardi E, Candelise L, Mannucci PM. Protein C in acute stroke. Stroke. 1988;19:579-583.
6. Feinberg WM, Brack DC, Ring ME, Corrigan JJ. Hemostatic markers in acute stroke. Stroke. 1989;20:582-587.
7. Fisher M, Francis R. Altered coagulation in cerebral ischemia: platelet, thrombin, and plasmin activity. Arch Neurol. 1990;47:1075-1079.
8. Tohgi H, Kawashima M, Tamura K, Suzuki H. Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism. Stroke. 1990;21:1663-1667.
9. Greaves M. Coagulation abnormalities and cerebral infarction. J Neurol Neurosurg Psychiatry. 1993;56:433-439.
10. Koudstall P, Ciabattoni G, van Gijn J, Niewenhuis H, de Groot P, Sixma P, Patrono C, Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke. 1993;24:219-222.
11. Yamazaki M, Uchiyama S, Maruyama S. Alterations of haemostatic markers in various subtypes and phases of stroke. Blood Coagul Fibrinolysis. 1993;4:707-712.
12. Weksler BB. Hematologic disorders and ischemic stroke. Curr Opin Neurol. 1995;8:38-44.
13. Takano K, Yamaguchi T, Kato H, Omae T. Activation of coagulation in acute cardioembolic stroke. Stroke. 1991;22:12-16.
14. Takano K, Yamaguchi T, Uchida K. Markers of a hypercoagulable state following acute ischemic stroke. Stroke. 1992;23:194-198.
15. Alkjaersig N, Fletcher AP. Catabolism and excretion of fibrinopeptide A. Blood. 1982;60:148-156.
16. Owen J, Kvam D, Nossel H, Kaplan KL, Kernoff PBA. Thrombin and plasmin activity and platelet activation in the development of venous thrombosis. Blood. 1983;60:476-482.
17. Whitaker AN, Elms MJ, Masci PP, Bundensen PG, Rylatt DB, Webber AJ, Bunce IH. Measurement of cross-linked fibrin derivatives in plasma: an immunoassay using monoclonal antibodies. J Clin Pathol. 1984;37:882-887.
18. Hunt FA, Rylatt DB, Hart R, Bundesen PG. Serum crosslinked fibrin (XDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems. Br J Haematol. 1985;60:715-722.
19. Rylatt DB, Blake AS, Cottis LE, Massingham DA, Fletcher WA, Masci PP, Whitaker AN, Elms M, Bunce I, Webber AJ, Wyatt D, Bundesen PG. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res. 1983;31:767-778.
20. Soria J, Soria C, Ryckewaert JJ. A solid phase immuno enzymological assay for the measurement of human fibrinopeptide A. Thromb Res. 1980;20:425-435.
21. Foulkes MA, Wolf PA, Price TP, Mohr JP, Hier DB. The Stroke Data Bank: design, methods, and baseline characteristics. Stroke. 1988; 19:547-554.
22. Norris JW. Comment on 'Study design of stroke treatments.' Stroke. 1982;13:527-528. Letter.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
24. Miller RG. Survival Analysis. New York, NY: John Wiley & Sons, Inc; 1981.
25. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972; 34:187-202.
26. Nossel HL. Relative proteolysis of fibrin Bβ chain by thrombin and plasmin as a determinant of thrombosis. Nature. 1981;291:165-167.
27. Kaplan KL, Owen J. Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood. 1981;57: 199-202.
28. Files JC, Malpass TW, Yee EK, Ritchie JL, Harker LA. Studies of human platelet alpha-granule release in vivo. Blood. 1981;58: 607-618.
29. Anzola GP, Magoni M, Ascari E, Maffi V. Early prognostic factors in ischemic stroke: the role of protein C and protein S. Stroke. 1993;24:1496-1500.
30. Broderick JP, Phillips SJ, O'Fallon M, Frye RL, Whisnant JP. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke. 1992;23:1250-1256.
31. Sacco SE, Whisnant JP, Broderick JP, Phillips SJ, O'Fallon WM. Epidemiological characteristics of lacunar infarcts in a population. Stroke. 1991;22:1236-1241.
32. Feinberg WM, Bruck DC, Jeter MA, Corrigan JJ. Fibrinolysis after acute ischemic stroke. Thromb Res. 1991;64:117-127.
33. Fisher M, Francis R. Altered coagulation in cerebral ischemia: platelet, thrombin, and plasmin activity. Arch Neurol. 1990;47:1075-1079.
34. Shah AB, Beamer N, Coull BM. Enhanced in vivo platelet activation in subtypes of ischemic stroke. Stroke. 1985;16:643-647.
35. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med. 1993;118: 956-963.
36. Cook NS, Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci Rev. 1990;11:444-451.
37. Ernst E. Plasma fibrinogen: an independent cardiovascular risk factor. J Intern Med. 1990;227:365-372.
38. Coull BM, Beamer N, de Garmo P, Sexton G, Nordt F, Knox R, Seaman VF. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke. 1991;22:162-168.
39. Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med. 1992;117:371-375.
40. Martin JF, Bath PM, Murr ML. Influence of platelet size on outcome after myocardial infarction. Lancet. 1992;338:1409-1411.
41. Banerjee AK, Pearson J, Gilliland EL, Goss D, Lewis JD, Stirling Y, Meade TW. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost. 1992;68:261-263.
42. Cahill M, Mistry R, Barnett DB. The human platelet fibrinogen receptor: clinical and therapeutic significance. Br J Clin Pharmacol. 1992;33:3-9.
43. Pizzo SV, Petruska DB, Doman KA, Soong S, Fuchs HE. Releasable vascular plasminogen activator and thrombotic strokes. Am J Med. 1985;79:407-411.
44. Juhan-Vague I, Valdier J, Alessi MC, Aillaud MF, Ansaldi C, Phillip-Joet C, Holvoet P, Serradimighi A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost. 1987;57:67-75.
45. Chimowitz MI, Mancini GBJ. Asymptomatic coronary artery disease in patients with stroke. Stroke. 1992;23:433-436.
46. Rankin J. Cerebrovascular accidents in patients over the age of 60, II: prognosis. Scott Med J. 1958;2:200-215.
47. Bounameaux H, de Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimer as a diagnostic aid in suspected venous thromboembolism: an overview. Thromb Haemost. 1994;71:1-6.